Linker Information

General Information of This Linker

Linker ID	LIN0PRXQW
Linker Name	NAD-based dinucleotide linker
Linker Type	Nucleotide linker
Antibody-Linker Relation	Uncleavable
Structure
Structure	3D MOL		2D MOL
Formula	C27H39ClN11O13P2+
Isosmiles	NCC1=CN(CCCNc2ncnc3c2ncn3C2OC(COP(=O)(O)OP(=O)(O)OCC3OC([n+]4cccc(C(N)=O)c4)C(Cl)C3O)C(O)C2O)NN1
InChI	InChI=1S/C27H38ClN11O13P2/c28-18-20(40)16(50-26(18)37-5-1-3-14(8-37)23(30)43)10-48-53(44,45)52-54(46,47)49-11-17-21(41)22(42)27(51-17)39-13-34-19-24(32-12-33-25(19)39)31-4-2-6-38-9-15(7-29)35-36-38/h1,3,5,8-9,12-13,16-18,20-22,26-27,35-36,40-42H,2,4,6-7,10-11,29H2,(H4-,30,31,32,33,43,44,45,46,47)/p+1
InChIKey	KXLUAOGUCUPRQY-UHFFFAOYSA-O
Pharmaceutical Properties	Molecule Weight	823.074	Polar area	337.36
	Complexity	54	xlogp Value	-2.4247
	Heavy Count	54	Rot Bonds	17
	Hbond acc	20	Hbond Donor	10

Each Antibody-drug Conjugate Related to This Linker

Full Information of The Activity Data of The ADC(s) Related to This Linker

DAR4-ARC-ADC [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	25.00 pM	Positive CLL-1 expression (CLL-1+++/++)
Method Description	In vitro cytotoxicity of the anti-hCLL-1 ARC-ADCs was then evaluated using human AML cell lines U937 (CLL-1+) and KG1a (CLL-1-1).
In Vitro Model	Adult acute monocytic leukemia	U-937 cells		CVCL_0007

DAR2-ARC-ADC [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.90 nM	Positive CLL-1 expression (CLL-1+++/++)
Method Description	In vitro cytotoxicity of the anti-hCLL-1 ARC-ADCs was then evaluated using human AML cell lines U937 (CLL-1+) and KG1a (CLL-1-1).
In Vitro Model	Adult acute monocytic leukemia	U-937 cells		CVCL_0007

References

Ref 1	Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy. J Control Release. 2021 Aug 10;336:433-442. doi: 10.1016/j.jconrel.2021.06.041.